Electroacupuncture for sepsis patients with ARDS
Electroacupuncture Modulates the Metabolism of SPMs and Ameliorates Respiratory Symptoms and Inflammation in Patients With Sepsis Complicating ARDS
This study is testing if electroacupuncture can help sepsis patients with breathing problems feel better and improve their symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tianjin Nankai Hospital Academic / other |
| Locations | 1 site (Tianjin, Tianjin) |
| Trial ID | NCT06006325 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of electroacupuncture on patients suffering from sepsis complicated by acute respiratory distress syndrome (ARDS). Participants will be divided into two groups: one receiving actual electroacupuncture treatment and the other receiving a sham treatment. The study aims to measure the impact of electroacupuncture on the synthesis of specialized pro-resolving mediators (SPMs) and respiratory symptoms in these patients. Objective outcome measures will be collected to assess the efficacy of the intervention.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 diagnosed with sepsis and ARDS within the last 48 hours.
Not a fit: Patients with severe comorbid conditions or those diagnosed with ARDS beyond 48 hours may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve respiratory symptoms and metabolic responses in sepsis patients with ARDS.
How similar studies have performed: While the approach of using electroacupuncture in this context is relatively novel, similar studies have shown promising results in related areas.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Males or females over the age of 18; 2. Diagnosis meets SPESIS 3 criteria for sepsis; 3. The diagnosis meets the Berlin diagnostic criteria for ARDS; 4. ARDS was diagnosed within 48h; 5. Capable of understanding the purpose and risk of the study; 6. Patients or proxy must give written informed consent before any assessment is performed. Exclusion Criteria: 1. ARDS was diagnosed 48h later; 2. Pregnancy, lactation or perinatal period; 3. malignant tumor; 4. Severe liver failure or kidney failure; 5. Predicted mortality risk of patients within 24h\>80%; 6. Severe end-stage lung disease; 7. ECMO patients are undergoing implementation; 8. HIV seropositive or Syphilis seropositive; 9. Any clinical-relevant condition that might affect study participation and/or study results; 10. Participation in any other intervention trial; 11. Unwillingness or inability to following the study protocol in the investigators opinion.
Where this trial is running
Tianjin, Tianjin
- Tianjin Nankai Hospital — Tianjin, Tianjin, China (Recruiting)
Study contacts
- Study coordinator: Jianbo Yu, MD
- Email: 30717008@nankai.edu.cn
- Phone: +8615344422323
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.